How I treat relapsed and refractory Hodgkin lymphoma

Blood

Volumn 117, Issue 16, 2011, Pages 4208-4217

  Kuruvilla, John ^a,b   Keating, Armand ^a,b   Crump, Michael ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; BORTEZOMIB; BRENTUXIMAB VEDOTIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FLUORODEOXYGLUCOSE; GEMCITABINE; IFOSFAMIDE; LOMUSTINE; MECLORETHAMINE; MELPHALAN; METHOTREXATE; MITOGUAZONE; NAVELBINE; PREDNISONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CHEMOTHERAPY INDUCED EMESIS; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; DRUG FATALITY; DRUG MEGADOSE; DRUG TOLERABILITY; EVENT FREE SURVIVAL; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LYMPHOMA EFFECT; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LONG TERM CARE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 79956028917     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-09-288373     Document Type: Review

References (105)

1. Armitage JO. Early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363(7):653-662.
2. Kuruvilla J. Standard therapy of advanced Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2009:497-506.
3. Lazarus HM, Rowlings PA, Zhang MJ, et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 1999;17(2):534-545. (Pubitemid 29075240)
4. André M, Henry-Amar M, Pico J-L, et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. J Clin Oncol. 1999;17(1):222.
5. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993;341(8852):1051-1054. (Pubitemid 23114397)
6. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002;359(9323):2065-2071. (Pubitemid 34680969)
7. National Comprehensive Cancer Network v2.2010 guideline on Hodgkin lymphoma. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed February 10, 2011.
8. Dryver ET, Jernstrom H, Tompkins K, Buckstein R, Imrie KR. Follow-up of patients with Hodgkin's disease following curative treatment: the routine CT scan is of little value. Br J Cancer. 2002;89(3):482-486. (Pubitemid 37026429)
9. Radford JA, Eardley A, Woodman C, Crowther D. Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records. BMJ. 1997;314(7077): 343.
10. Torrey M, Poen J, Hoppe R. Detection of relapse in early-stage Hodgkin's disease: role of routine follow-up studies. J Clin Oncol. 1997;15(3):1123-1130. (Pubitemid 27106298)
11. Goldschmidt N, Or O, Klein M, Savitsky B, Paltiel O. The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. Ann Hematol. 2011;90:165-171.
12. Zinzani PL, Stefoni V, Tani M, et al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol. 2009;27(11):1781-1787.
13. Zinzani PL, Tani M, Trisolini R, et al. Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. Haematologica. 2007;92(6): 771-777. (Pubitemid 350155302)
14. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571-578. (Pubitemid 350002965)
15. Moskowitz CH, Schöder H, Teruya-Feldstein J, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-cell lymphoma. J Clin Oncol. 2010;28(11):1896-1903.
16. Kobe C, Dietlein M, Franklin J, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood. 2008;112(10):3989-3994.
17. Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood. 2000;96(4):1280-1286. (Pubitemid 30658456)
18. Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol. 2002;20(1):221-230. (Pubitemid 34032615)
19. Martín A, Fernandez-Jimenez MC, Caballero MD, et al. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. Br J Haematol. 2001;113(1):161-171. (Pubitemid 32423317)
20. Crump M, Smith AM, Brandwein J, et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. J Clin Oncol. 1993;11(4):704-711. (Pubitemid 23105679)
21. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97(3):616-623. (Pubitemid 32113392)
22. Brice P, Bastion Y, Divine M, et al. Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients. Cancer. 1996;78(6): 1293-1299. (Pubitemid 26303897)
23. Fermé C, Bastion Y, Lepage E, et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann Oncol. 1995;6(6):543-549.
24. Lohri A, Barnett M, Fairey RN, et al. Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988. Blood. 1991;77(10):2292-2298.
25. Bierman PJ, Lynch JC, Bociek RG, et al. The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol. 2002;13(9):1370-1377.
26. Reece DE, Barnett MJ, Shepherd JD, et al. Highdose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood. 1995;86(2):451-456.
27. Pfreundschuh MG, Rueffer U, Lathan B, et al. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. J Clin Oncol. 1994;12(3):580-586. (Pubitemid 24079902)
28. Colwill R, Crump M, Couture F, et al. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol. 1995;13(2):396-402.
29. Rodriguez J, Rodriguez MA, Fayad L, et al. ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Blood. 1999; 93(11):3632-3636. (Pubitemid 29249808)
30. Ribrag V, Nasr F, Bouhris JH, et al. VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease. Bone Marrow Transplant. 1998;21(10):969-974. (Pubitemid 28230659)
31. Josting A, Rudolph C, Reiser M, et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol. 2002;13(10):1628-1635. (Pubitemid 35331462)
32. Baetz T, Belch A, Couban S, et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 2003;14(12):1762-1767. (Pubitemid 38029048)
33. Chau I, Harries M, Cunningham D, et al. Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma. Br J Haematol. 2003;120(6):970-977. (Pubitemid 36411555)
34. Fermé C, Mounier N, Divine M, et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol. 2002;20(2):467-475. (Pubitemid 34072531)
35. Proctor SJ, Jackson GH, Lennard A, et al. Strategic approach to the management of Hodgkin's disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK). Ann Oncol. 2003;14(suppl 1):i47-50.
36. Bonfante V, Viviani S, Devizzi L, et al. High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease. Eur J Haematol Suppl. 2001;64:51-55. (Pubitemid 32589052)
37. Kuruvilla J, Nagy T, Pintilie M, Tsang R, Keating A, Crump M. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer. 2006;106(2):353-360. (Pubitemid 43100444)
38. Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol. 2007;18(6):1071-1079. (Pubitemid 47053777)
39. Bonfante V, Viviani S, Santoro A, et al. Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease. Br J Haematol. 1998;103(2):533-535. (Pubitemid 28522464)
40. Puig N, Pintilie M, Seshadri T, et al. Different response to salvage chemotherapy but similar posttransplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma. Haematologica. 2010;95(9):1496-1502.
41. Moskowitz CH, Kewalramani T, Nimer SD, Gonzalez M, Zelenetz AD, Yahalom J. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsyproven primary refractory Hodgkin's disease. Br J Haematol. 2004;124(5):645-652. (Pubitemid 38297098)
42. Akhtar S, El Weshi A, Abdelsalam M, et al. Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients. Bone Marrow Transplant. 2007;40(7):651-658. (Pubitemid 47456479)
43. Czyz J, Szydlo R, Knopinska-Posluszny W, et al. Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy. Bone Marrow Transplant. 2004;33(12):1225-1229. (Pubitemid 38961481)
44. Brandwein JM, Callum J, Sutcliffe SB, Scott JG, Keating A. Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease. Bone Marrow Transplant. 1990;5(2):99-103. (Pubitemid 20116086)
45. Stewart AK, Brandwein JM, Sutcliffe SB, Scott JG, Keating A. Mini-beam as salvage chemotherapy for refractory Hodgkin's disease and non-Hodgkin's lymphoma. Leuk Lymphoma. 1991;5(2-3):111-115.
46. Ardeshna KM, Kakouros N, Qian W, et al. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. Br J Haematol. 2005;130(3):363-372. (Pubitemid 43899584)
47. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.
48. Dreger P, Kloss M, Petersen B, et al. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood. 1995;86(10): 3970-3978.
49. Watts MJ, Sullivan AM, Jamieson E, et al. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol. 1997;15(2):535-546. (Pubitemid 27074220)
50. Weaver CH, Zhen B, Buckner CD. Treatment of patients with malignant lymphoma with Mini-BEAM reduces the yield of CD34+ peripheral blood stem cells. Bone Marrow Transplant. 1998; 21(11):1169-1170. (Pubitemid 28256663)
51. Jabbour E, Hosing C, Ayers G, et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer. 2007;109(12):2481-2489. (Pubitemid 46906468)
52. Moskowitz AJ, Yahalom J, Kewalramani T, et al. Pre-transplant functional imaging predicts outcome following autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma. Blood. 2010;116(23):4934-4937.
53. Castagna L, Bramanti S, Balzarotti M, et al. Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy. Br J Haematol. 2009;145(3):369-372.
54. Schot BW, Zijlstra JM, Sluiter WJ, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood. 2007;109(2):486-491. (Pubitemid 46105942)
55. Stewart DA, Guo D, Gluck S, et al. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant. 2000;26(4):383-388. (Pubitemid 30649553)
56. Stuart MJ, Chao NS, Horning SJ, et al. Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. Biol Blood Marrow Transplant. 2001;7(10):552-560. (Pubitemid 33107565)
57. Bierman PJ, Bagin RG, Jagannath S, et al. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: longterm follow-up in 128 patients. Ann Oncol. 1993; 4(9):767-773. (Pubitemid 23340088)
58. Reece DE, Nevill TJ, Sayegh A, et al. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease. Bone Marrow Transplant. 1999;23(11):1131-1138. (Pubitemid 29259669)
59. Josting A, Rudolph C, Mapara M, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol. 2005;16(1):116-123. (Pubitemid 40124488)
60. Evens A, Altman J, Mittal B, et al. Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma. Ann Oncol. 2007;18(4):679-688. (Pubitemid 46523271)
61. Josting A, Mü ller H, Borchmann P, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol. 2010;28: 5074-5080.
62. Josting A. Autologous transplantation in relapsed and refractory Hodgkin's disease. Eur J Haematol Suppl. 2005(66):141-145. (Pubitemid 40873992)
63. Fung HC, Stiff P, Schriber J, et al. Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma. Biol Blood Marrow Transplant. 2007; 13(5):594-600. (Pubitemid 46585934)
64. Morschhauser F, Brice P, Ferme C, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 Trial by the GELA/SFGM Study Group. J Clin Oncol. 2008; 26(36):5980-5987.
65. Josting A, Nogova L, Franklin J, et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol. 2005;23(7):1522-1529.
66. Brada M, Eeles R, Ashley S, Nichols J, Horwich A. Salvage radiotherapy in recurrent Hodgkin's disease. Ann Oncol. 1992;3(2):131-135.
67. Campbell B, Wirth A, Milner A, Di Iulio J, MacManus M, Ryan G. Long-term follow-up of salvage radiotherapy in Hodgkin's lymphoma after chemotherapy failure. Int J Radiat Oncol Biol Phys. 2005;63(5):1538-1545. (Pubitemid 41628054)
68. Leigh BR, Fox KA, Mack CF, Baier M, Miller TP, Cassady JR. Radiation therapy salvage of Hodgkin's disease following chemotherapy failure. Int J Radiat Oncol Biol Phys. 1993;27(4):855-862. (Pubitemid 23340297)
69. Pezner RD, Lipsett JA, Vora N, Forman SJ. Radical radiotherapy as salvage treatment for relapse of Hodgkin's disease initially treated by chemotherapy alone: prognostic significance of the disease-free interval. Int J Radiat Oncol Biol Phys. 1994;30(4):965-970. (Pubitemid 24355949)
70. MacMillan CH, Bessell EM. The effectiveness of radiotherapy for localized relapse in patients with Hodgkin's disease (IIB-IVB) who obtained a complete response with chemotherapy alone as initial treatment. Clin Oncol (R Coll Radiol). 1994;6(3): 147-150.
71. Uematsu M, Tarbell NJ, Silver B, et al. Wide-field radiation therapy with or without chemotherapy for patients with Hodgkin disease in relapse after initial combination chemotherapy. Cancer. 1993; 72(1):207-212. (Pubitemid 23182074)
72. Fermé C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 2007;357(19): 1916-1927. (Pubitemid 350074687)
73. Press OW, LeBlanc M, Lichter AS, et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol. 2001;19(22): 4238-4244. (Pubitemid 33081641)
74. Sieber M, Franklin J, Tesch H. Two cycles ABVD plus extended field radiotherapy is superior to radiotherapy alone in early stage Hodgkin's disease: results of the German Hodgkin's Lymphoma Study Group (GHSG) Trial HD7 [abstract]. Blood. 2002;100:93a: Abstract 341.
75. Tsang RW, Gospodarowicz MK, Sutcliffe SB, Crump M, Keating A. Thoracic radiation therapy before autologous bone marrow transplantation in relapsed or refractory Hodgkin's disease. PMH Lymphoma Group, and the Toronto Autologous BMT Group. Eur J Cancer. 1999;35(1):73-78. (Pubitemid 29079494)
76. Bonfante V, Santoro A, Viviani S, et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol. 1997;15(2): 528-534. (Pubitemid 27074219)
77. Schellong G, Dorffel W, Claviez A, et al. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. J Clin Oncol. 2005;23(25):6181-6189.
78. Gajewski JL, Phillips GL, Sobocinski KA, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol. 1996;14(2):572-578. (Pubitemid 26051023)
79. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003;31(8):667-678. (Pubitemid 36553477)
80. Anderson JE, Litzow MR, Appelbaum FR, et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol. 1993;11(12): 2342-2350. (Pubitemid 23353963)
81. Akpek G, Ambinder RF, Piantadosi S, et al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol. 2001; 19(23):4314-4321. (Pubitemid 33096779)
82. Anderlini P, Acholonu SA, Okoroji GJ, et al. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response. Bone Marrow Transplant. 2004;34(6): 511-514. (Pubitemid 39264041)
83. Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet. 2005;365(9475):1934-1941. (Pubitemid 40797503)
84. Peggs KS, Sureda A, Qian W, et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol. 2007;139(1): 70-80. (Pubitemid 47389932)
85. Alvarez I, Sureda A, Caballero MD, et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a spanish prospective cooperative protocol. Biol Blood Marrow Transplant. 2006;12(2):172-183. (Pubitemid 43138012)
86. Anderlini P, Saliba R, Acholonu S, et al. Fludarabinemelphalan as a preparative regimen for reducedintensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica. 2008;93(2): 257-264. (Pubitemid 351397714)
87. Burroughs LM, Paul VOD, Brenda MS, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14(11):1279- 1287.
88. Devetten MP, Parameswaran NH, Jeanette C, et al. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2009;15(1):109-117.
89. Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26(3):455-462. (Pubitemid 351171699)
90. Sureda A, Canals C, Arranz R, et al. Allogeneic Stem Cell Transplantation After Reduced Intensity Conditioning (RIC-allo) in Patients with Relapsed or Refractory Hodgkin's Lymphoma (HL). Final Analysis of the HDR-Allo Protocol - A Prospective Clinical Trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT). ASH Ann Meeting Abstr. 2009;114(22): Abstract 658.
91. Thomson KJ, Peggs KS, Smith P, et al. Improved outcome following reduced intensity allogeneic transplantation in Hodgkin's lymphoma relapsing post-autologous transplantation. Blood. 2005; 106: Abstract 657.
92. Castagna L, Sarina B, Todisco E, et al. Allogeneic stem cell transplantation compared with chemotherapy for poor-risk Hodgkin lymphoma. Biol Blood Marrow Transplant. 2009;15(4):432-438.
93. Smith SM, van Besien K, Carreras J, et al. Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant. 2008;14(8): 904-912. (Pubitemid 351985028)
94. Little R, Wittes RE, Longo DL, Wilson WH. Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant. J Clin Oncol. 1998;16(2):584-588. (Pubitemid 28135603)
95. Zinzani PL, Bendandi M, Stefoni V, et al. Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. Haematologica. 2000;85(9):926-929.
96. Blum KA, Johnson JL, Niedzwiecki D, Cannellos GP, Cheson BD, Bartlett NL.Aphase II study of bortezomib in relapsed Hodgkin lymphoma: preliminary results of CALGB 50206. J Clin Oncol. 2006;24(No. 18S [June 20 suppl]):7576.
97. Kuruvilla J, Song K, Mollee P, et al. A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma. Hematology. 2006;11(1):25-29. (Pubitemid 43354956)
98. Pro B, Younes A, Albitar M, et al. Thalidomide for patients with recurrent lymphoma. Cancer. 2004; 100(6):1186-1189. (Pubitemid 38325946)
99. Younes A, Pro B, Romaguera J, Dang N. Safety and efficacy of bortezomib (Velcade) for the treatment of relapsed classical Hodgkin's disease. Blood. 2004;104(11):2638.
100. Younes A. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2009(1):507-519.
101. Younes A, Romaguera J, Hagemeister F, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer. 2003;98(2): 310-314. (Pubitemid 36828455)
102. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19): 1812-1821.
103. Johnston PB, Inwards DJ, Colgan JP, et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010;85(5):320-324.
104. Younes A, Ong T-C, Ribrag V, et al. Efficacy of panobinostat in phase II study in patients with relapsed/refractory Hodgkin lymphoma (HL) after high-dose chemotherapy with autologous stem cell transplant. ASH Ann Meeting Abstr. 2009; 114(22): Abstract 923.
105. Fehniger TA, Larson S, Trinkaus K, et al. A phase II multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. ASH Ann Meeting Abstr. 2009;114(22): Abstract 3693.